The European Medicines Agency’s (EMA) has recommended suspending the marketing authorisation of Velactis, a treatment used to reduce milk production in dairy cows at drying off.

Dairy cow.
Velactis is used to reduce milk production at drying off.

The Committee for Medicinal Products for Veterinary Use (CVMP) recommendation follows reports of adverse events in 319 dairy cows after treatment with Velactis.

Adverse events

Many of the adverse events were serious, including recumbency in 208 animals, which generally occurred within 24 hours of administering Velactis. In total, 71 deaths were reported in cows – most after a period of recumbency.

Although the exact cause of these adverse events is yet to be determined, there is evidence to suggest they may be linked to the use of Velactis.

Given the number and severity of adverse events following use of the medicine in otherwise healthy dairy cows, the committee concluded that, at present, the risks outweigh the benefits of the product.

The CVMP therefore recommended the marketing authorisation for Velactis be suspended in the EU until further information is available to show the benefits outweigh the risks – possibly under new conditions of use or restrictions.

Recall

The committee also recommended, as a precautionary measure, a recall of Velactis currently on the market in the EU. The use of the medicine has already been suspended by national authorities in some EU member states and the company has informed EMA it has suspended sales in the EU.

The CVMP’s recommendations will now be sent to the European Commission for a legally binding decision applicable in all EU member states.

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz

related content

The UK’s largest group of independent practices has announced it has put well-being at the top of its agenda for 2017.

Staff at a Lincolnshire practice have made a clean sweep in collecting all five “outstanding” awards open to it under the RCVS Practice Standards Scheme.

Ceva Santé Animale has gained a diversified portfolio of products from Boehringer Ingelheim following its acquisition of Merial Animal Health.

A memorial service for veterinary surgeon and former RCVS president Bob Michell will be held on Friday 10 March.

2 mins

Leadership, innovation and culture change are the central themes in the RCVS' three-year strategic plan, which was published on 16 January.

6 mins

The 2017 edition of the NOAH Compendium of Data Sheets for Animal Medicines is now available.

4 mins